<SEC-DOCUMENT>0001213900-24-100364.txt : 20241120
<SEC-HEADER>0001213900-24-100364.hdr.sgml : 20241120
<ACCEPTANCE-DATETIME>20241120080227
ACCESSION NUMBER:		0001213900-24-100364
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241120
FILED AS OF DATE:		20241120
DATE AS OF CHANGE:		20241120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		241478321

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea022170301-6k_enlivex.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">For the month of: November 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On November 20, 2024, Enlivex Therapeutics Ltd., a
company organized under the laws of the State of Israel (&ldquo;Enlivex&rdquo;), issued a press release announcing that  Enlivex&rsquo;s
board of directors approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy. A copy of such press
release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U><A HREF="ea022170301ex99-1_enlivex.htm">Press Release issued by Enlivex Therapeutics Ltd. on November 20, 2024.</A></U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Name:&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Title:</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Date: November 20, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea022170301ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON NOVEMBER 20, 2024.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 42px; width: 150px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Enlivex Adopts Bitcoin Treasury Reserve Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Nes-Ziona, Israel, November 20, 2024 (GLOBE NEWSWIRE)
-- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming immunotherapy company,
today announced that the Company&rsquo;s Board of Directors approved the purchase of up to&nbsp;$1 million&nbsp;of Bitcoin as part of
its cash management strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&ldquo;As demand for Bitcoin has grown, together with
its rising acceptance as a recognized medium of exchange, we believe that Bitcoin will serve the Company as a strong and diversifying
treasury reserve asset,&rdquo; said&nbsp;Oren Hershkovitz, CEO of Enlivex. &ldquo;With the recent approvals of Bitcoin ETFs and growing
support from institutional investors, we believe that Bitcoin can provide the Company with a potential functional store of value and an
inflation hedge to standard currencies.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>ABOUT ENLIVEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Enlivex is a clinical stage macrophage reprogramming
immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their
homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution
of life-threatening and life debilitating conditions. For more information, visit&nbsp;https://enlivex.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo; and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRA<SUP>TM</SUP> programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may affect Enlivex&rsquo;s business and prospects, including the risks
that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail,
may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these
products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any
activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.
The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in
animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development
of any products using the ALLOCETRA<SUP>TM</SUP> product line could also be affected by a number of other factors, including unexpected
safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical
industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental,
technological and other factors discussed in Enlivex&rsquo;s filings with the Securities and Exchange Commission, including in the Company&rsquo;s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in
this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>ENLIVEX CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Shachar Shlosberger, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Enlivex Therapeutics, Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>INVESTOR RELATIONS CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Dave Gentry, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">RedChip Companies Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">1-407-644-4256</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">ENLV@redchip.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M/A%-/*D$47C6R9Y9&VJJ[)?XJ];A^(/A4#_D8]('_;[%_P#%5SSM[*#:OO\
MF=%.ZQ$TI6V_(M>,O"NG^-O"FJZ#JD?G:?J%L]M/'ZJPP:^3OV6;6^^('Q,E
M/B/5[75_^%96K:%I:P2;Q.S.R?;#[F*-$W?6O9_V@OBA/X<^'45OX8E2_P#$
MGB>:/2M#\B3<&EE^7S=R_P *+N?=["O-/$7P[MOV6+KX?^-='!.DZ;!%X?\
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>EI%:Q%_O,$4+D_E^M%=&U%?)RJ2;N?=0HQ44C__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
